Oxford BioMedica PLC
LSE:OXB
Oxford BioMedica PLC
Oxford Biomedica Plc is a biopharmaceutical company, which engages in the research and development of gene and cell therapy. The company is headquartered in Oxford, Oxfordshire. The firm and its subsidiaries have developed lentiviral vector delivery system, LentiVector platform, which the Company leverages to develop in vivo and ex vivo products both in-house and with partners. Its LentiVector delivery platform has created a portfolio of gene and cell therapy product candidates in the areas of oncology, ophthalmology, central nervous system (CNS) disorders and liver diseases. The firm's product pipeline includes OXB-302, OXB-203, OXB-204 and OXB-103 and OXB-401. The firm has also developed partnership with various pharmaceutical companies to develop potential gene and cell therapy products. Its partnered products include AXO-LENTI-PD, SAR 422459 and SAR421869.
Oxford Biomedica Plc is a biopharmaceutical company, which engages in the research and development of gene and cell therapy. The company is headquartered in Oxford, Oxfordshire. The firm and its subsidiaries have developed lentiviral vector delivery system, LentiVector platform, which the Company leverages to develop in vivo and ex vivo products both in-house and with partners. Its LentiVector delivery platform has created a portfolio of gene and cell therapy product candidates in the areas of oncology, ophthalmology, central nervous system (CNS) disorders and liver diseases. The firm's product pipeline includes OXB-302, OXB-203, OXB-204 and OXB-103 and OXB-401. The firm has also developed partnership with various pharmaceutical companies to develop potential gene and cell therapy products. Its partnered products include AXO-LENTI-PD, SAR 422459 and SAR421869.
Revenue Growth: OXB reported first half 2025 revenues of GBP 73.2 million, up 44% year-on-year, reflecting strong demand and momentum in cell and gene therapy CDMO services.
Order Book Surge: Contracted client orders reached GBP 149 million for H1, up 166% from the prior year, providing significant revenue visibility into 2025 and beyond.
Profitability Improvement: Operating EBITDA loss narrowed sharply to GBP 8.3 million from GBP 20.3 million a year ago, driven by higher revenues and disciplined cost control.
Strengthened Balance Sheet: Post-period, OXB raised GBP 60 million via equity and secured a new $125 million loan facility to fund strategic investments and capacity expansion, especially in the US.
Upgraded Guidance: OXB reiterated and upgraded its medium-term guidance, targeting 2025 revenues of GBP 160–170 million and sustainable profitability, with longer-term revenue CAGR of 25–30%.
Pipeline Advancement: The late-stage client pipeline is growing, with five late-stage clinical programs expected to move towards commercial stage, supporting future revenue growth.
Diversified Client Base: Customer growth is increasingly global and diversified by vector type, with all new H1 clients in AAV and a greater geographic spread beyond North America.
